Skip to content
  • News & Events
    • Recent News & Events
    • Press & Media
  • Culture
    • Careers
  • Partnering
  • Investors
    • Overview
    • News & Events
      • Press Releases
      • Events & Presentations
    • Governance
      • Governance Overview
      • Board of Directors
      • Management
      • Committee Composition
      • Board Diversity Matrix
    • Financials
      • SEC Filings
      • Quarterly Results
      • Annual Reports
    • Stock Information
      • Stock Information
      • Analyst Coverage
    • Investor Resources
      • Email Alerts
      • Investor Contacts
  • Contact
Menu
  • News & Events
    • Recent News & Events
    • Press & Media
  • Culture
    • Careers
  • Partnering
  • Investors
    • Overview
    • News & Events
      • Press Releases
      • Events & Presentations
    • Governance
      • Governance Overview
      • Board of Directors
      • Management
      • Committee Composition
      • Board Diversity Matrix
    • Financials
      • SEC Filings
      • Quarterly Results
      • Annual Reports
    • Stock Information
      • Stock Information
      • Analyst Coverage
    • Investor Resources
      • Email Alerts
      • Investor Contacts
  • Contact
  • Science
    • Barriers to Treatment in the Liver
    • Barriers to Treatment in the Pancreas
    • Overcoming Immunosuppression
    • Overcoming Intratumoral Pressure
    • Publications & Presentations
  • Platform
    • Drug Delivery Technology
  • Pipeline
    • Candidate nelitolimod
  • Clinical Trials
  • For Patients
  • About
Menu
  • Science
    • Barriers to Treatment in the Liver
    • Barriers to Treatment in the Pancreas
    • Overcoming Immunosuppression
    • Overcoming Intratumoral Pressure
    • Publications & Presentations
  • Platform
    • Drug Delivery Technology
  • Pipeline
    • Candidate nelitolimod
  • Clinical Trials
  • For Patients
  • About
Menu
  • Science
    • Innovative Treatments for Liver & Pancreatic Tumors
    • Barriers to Treatment in the Liver
    • Barriers to Treatment in the Pancreas
    • Overcoming Immunosuppression
    • Overcoming Intratumoral Pressure
    • Publications & Presentations
  • Platform
    • Platform
    • Drug Delivery Technology
  • Pipeline
    • Our Pipeline
    • Candidate nelitolimod
  • Clinical Trials
  • For Patients
  • About
  • News & Events
    • Recent News & Events
    • Press & Media
  • Culture
    • The Trisalus Culture
    • Careers
  • Partnering
  • Investors
    • Overview
    • News & Events
      • Press Releases
      • Events & Presentations
    • Governance
      • Governance Overview
      • Board of Directors
      • Management
      • Committee Composition
      • Board Diversity Matrix
    • Financials
      • SEC Filings
      • Quarterly Results
      • Annual Reports
    • Stock Information
      • Stock Information
      • Analyst Coverage
    • Investor Resources
      • Email Alerts
      • Investor Contacts
  • Contact
Back to Leadership
  • OUR TEAM

Richard Marshall

  • Medical Director

Dr Richard Marshall was appointed as Medical Director in January 2025. Dr. Marshall is an Interventional Radiologist who continues to have an active outpatient and inpatient practice.

After graduating from Tulane University School of Medicine, he completed his residency at Ochsner Clinic Foundation in Diagnostic Radiology where he served as Chief Resident. He continued specialization in Interventional Radiology and Interventional Oncology as a fellow at Weill Cornell University and Memorial Sloan Kettering Cancer Center in New York. After graduating from fellowship, he worked at Louisiana State University Health Sciences Center in New Orleans, Louisiana for seven years. He developed the state’s first Interventional Radiology Residency and led a busy clinical practice that specialized in interventional oncology, hepatobiliary interventions, and trauma care. Dr. Marshall began working at Tulane University School of Medicine in 2021, where he is active in medical student and resident education. His clinical practice includes care for patients undergoing organ transplantation, interventional oncology, pediatric care, embolization for thyroid disease, uterine fibroids, and musculoskeletal pain palliation, as well as venous interventions, and palliative care.

Image of Richard Marshall.
© 2024 TriSalus Life Sciences, Inc. All rights reserved
  • Privacy Policy
  • Compliance
  • Terms of Use
Linkedin Twitter
Linkedin Twitter
© 2023 TriSalus Life Sciences, Inc.
All rights reserved
  • Privacy Policy
  • Compliance
  • Terms of Use

IMPORTANT NOTICE

You are now leaving the Trisalus life Sciences corporate website.

We encourage you to read and evaluate terms of use, privacy, security and other similar policies of the destination site as they may differ from TriSalus’ standards.

Third Party Sites

TriSalus assumes no responsibility nor does it control, endorse or guarantee any aspect of your use of any third party sites. Additionally, the presence of this link does not imply the third party site’s endorsement of TriSalus or this website.

Thank you for visiting our site.

YES
CANCEL